Companies · Other Health Care
St. Louis · Other Health Care
Diligence memoA one-page analyst read on Navvis & Company, LLC — recommendation, valuation, rhythm, risks.→Navvis & Company, LLC looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Navvis & Company, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Navvis & Company, LLC is one of 5377 Other Health Care companies tracked from St. Louis. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 97% of sector peers (real $). Modeled value above 98% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 46.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Avail Medsystems, Inc. | Series C | $126.7M | $2.2B | 1.87× |
| Whoop, Inc. | Series C | $180.4M | $2.1B | 1.81× |
| HRGi Holdings, Inc. | Series C | $91.2M | $2.1B | 1.81× |
| Ambulnz, Inc. | Series C | $90.0M | $2.1B | 1.79× |
| MedAvail, Inc. | Series C | $97.0M | $2.0B | 1.75× |
| SOC Telemed, Inc. | Series C | $103.0M | $1.9B | 1.65× |
| Eargo, Inc. | Series C | $187.4M | $1.9B | 1.61× |
| Truth Holdings, L.P. | Series C | $88.8M | $1.6B | 1.43× |
| NeuroPace Inc | Series C | $208.6M | $1.5B | 1.33× |
| DermTech, Inc. | Series C | $98.9M | $1.5B | 1.29× |
| Mydna, Inc | Series C | $72.1M | $1.4B | 1.26× |
| Ancora Heart, Inc. | Series C | $151.3M | $1.4B | 1.24× |
| Navvis & Company, LLC this company | Series C | $133.9M | $1.3B | 1.12× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $9.9M | 2015-10-30 | $45.0M | $199.8M | 85% |
| Series A | $5.0M | 2016-10-27 | $22.7M | $100.9M | 90% |
| Series A | $4.0M | 2019-06-28 | $18.2M | $80.7M | 90% |
| Series A | $10.0M | 2019-10-31 | $45.5M | $201.8M | 90% |
| Series A | $10.0M | 2020-09-25 | $45.5M | $185.6M | 90% |
| Series A | $15.0M | 2021-06-04 | $68.2M | $217.4M | 90% |
| Series C | $80.0M | 2021-11-17 | $533.3M | $1.3B | 90% |
| Series C | $80.0M | 2021-11-17 | $533.3M | $1.3B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Stuart B. Baker, MD | — | 1 other | 2016-10 |
| Timothy L. Elliott | — | 1 other | 2015-10 |
| Courtney J. Fortner | — | — | 2021-06 |
| Dawn D. Owens | — | — | 2015-10 |
| Dawn L. Owens | — | — | 2019-10 |
| Mark J. Mugiishi | — | — | 2021-06 |
| Mark L. Mugiishi | — | — | 2019-10 |
| Michael R. Farris | — | — | 2015-10 |
| Miles J. Snowden | — | — | 2021-06 |
| Randall J. Combs | — | — | 2015-10 |
| Robert D. Bauer | — | — | 2015-10 |
| Robert L. Bauer | — | — | 2021-06 |
| Steve J. Smoot | — | — | 2021-06 |
| Stuart B. Baker | — | — | 2015-10 |
| Stuart J. Baker | — | — | 2021-06 |
Navvis & Company, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Alphatec Holdings, Inc. | Other Health Care | Series C | $133.7M | $608.7M | same sector · same stage |
| Vertiflex, Inc. | Other Health Care | Series C | $134.1M | $1.0B | same sector · same stage |
| Rapid Micro Biosystems, Inc. | Other Health Care | Series C | $134.6M | $1.4B | same sector · same stage |
| SpyGlassPharma, Inc. | Other Health Care | Series C | $134.8M | $485.1M | same sector · same stage |
| Veran Medical Technologies, Inc. | Other Health Care | Series C | $130.9M | $953.8M | same sector · same stage |
| BioDerm Holdings, LP | Other Health Care | Series C | $130.9M | $1.0B | same sector · same stage |
| Cardiomems Inc | Other Health Care | Series C | $139.6M | $1.4B | same sector · same stage |
| Drconsulta Ltd. | Other Health Care | Series C | $140.1M | $837.3M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Nava Management, LLC | Other Health Care | Seed | $46.0M | 91% |
| Naavacare LLC | Other Health Care | Pre-Seed | $2.7M | 89% |
| Navierre Holdings, LLC | Other Health Care | Seed | $924K | 89% |
| Navigantis, Inc. | Other Health Care | Series A | $46.6M | 87% |
| PAVmed Inc. | Other Health Care | Series B | $120.7M | 84% |
| Vrhspv Llc | Other Health Care | Pre-Seed | $476K | 84% |
| Vyvve, LLC | Other Health Care | Seed | $26.5M | 84% |
| Nava Health Md, Inc. | Healthtech | Seed | $458K | 84% |
See where Navvis & Company, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Navvis & Company, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.